Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central anxious method, conolidine modulates alternate molecular targets. A Science Advances review discovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/